TH E O H I O STATE U N I V E R S I TY ME D ICAL C EN TER
Another development to treat “congested” heart failure patients outside the hospital is outpatient ultrafiltration therapy. Ohio State is the only facility in central Ohio providing this therapy in the outpatient setting.
PATIENT SURVIVAL
100% 90%
Transplant Ohio State offers one of only two comprehensive heart transplant programs in Ohio. In the last several years, an average of 12 patients have been transplanted each year. Patient survival at one year after transplant averages 83 percent for January 2008 – June 2010. Survival at three years for July 2005 – December 2007 is 86 percent. Since the program was founded in 1986, surgeons have performed more than 350 heart transplant operations. The Ohio State team dedicated to caring for heart failure patients excels in providing the medical, pharmacologic and psychosocial support necessary to optimize the health and well-being of these complicated patients while they await the extraordinary—a lifesaving heart transplant. In keeping with its strong commitment to advance education and training, Ohio State offers a fellowship in heart failure and transplantation.
83%
86%
80% 70% 60% 50% 40% 30% 20% 10% 0%
One-year Post Transplant
Three-years Post Transplant
TOTAL TRANSPLANTS (since 1986)
350
Ventricular Assist Devices (VADs) Only 10 percent of patients referred for evaluation for transplant are determined to be suitable candidates. Some patients awaiting transplant (bridge to transplant) and some who are not appropriate for transplant (destination therapy) are candidates for mechanical circulatory support with ventricular assist devices or VADs. The VAD program at Ohio State currently cares for more than 70 end-stage heart failure patients on long-term support, making it one of the busiest programs in the region. Ohio State’s VAD program was one of the first to be certified by The Joint Commission accrediting body and recently received recertification. The current one-year survival in the program is 80 percent for patients with chronic VAD support.
27